Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 8%
Buy 25%
Hold 58%
Sell 8%
Strong Sell 0%

Bulls say

Amgen has demonstrated robust financial performance, with sales increasing by 40% in 3Q25 compared to the same quarter in the previous year, driven by strong gains in key products such as Repatha and Tezspire. Additionally, management's guidance indicates an R&D growth of over 20% for 2025, which underscores the company's commitment to expanding its innovative pipeline and enhancing its market position. The raise in FY25 revenue guidance from $35.0-$36.0 billion to $35.8-$36.6 billion reflects the firm’s sustained strength across its established drug franchises and the positive impact of recent acquisitions.

Bears say

The analysis highlights a concerning outlook for Amgen as total revenue is projected to grow by only approximately 1% from 2025 to 2026, primarily due to significant expected sales declines for critical products such as Prolia and Xgeva, estimated at about 28% and 39%, respectively. Additionally, the company's research and development expenditures are anticipated to grow at a slower rate which could hinder the pipeline's ability to compensate for the erosion of its established product franchises due to impending losses of exclusivity. Despite Amgen's current position as a high-quality, defensive large-cap biotech company with stable near-term cash flows, the lack of long-term growth drivers raises concerns about its sustainability amidst structural challenges.

Amgen (AMGN) has been analyzed by 12 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 25% recommend Buy, 58% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 12 analysts, Amgen (AMGN) has a Hold consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $322.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $322.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.